Higher Dose Oral Fluconazole for the Treatment of AIDS-related Cryptococcal Meningitis (HIFLAC)—report of A5225, a multicentre, phase I/II, two-stage, dose-finding, safety, tolerability and efficacy randomised, amphotericin B-controlled trial of the AIDS Clinical Trials Group

MLA

Lalloo, Umesh G., et al. “Higher Dose Oral Fluconazole for the Treatment of AIDS-Related Cryptococcal Meningitis (HIFLAC)—report of A5225, a Multicentre, Phase I/II, Two-Stage, Dose-Finding, Safety, Tolerability and Efficacy Randomised, Amphotericin B-Controlled Trial of the AIDS Clinical Trials Group.” PLoS ONE, vol. 17, no. 2, Feb. 2023, pp. 1–21. EBSCOhost, https://doi.org/10.1371/journal.pone.0281580.

APA

Lalloo, U. G., Komarow, L., Aberg, J. A., Clifford, D. B., Hogg, E., McKhann, A., Bukuru, A., Lagat, D., Pillay, S., Mave, V., Supparatpinyo, K., Samaneka, W., Langat, D., Ticona, E., Badal-Faesen, S., & Larsen, R. A. (2023). Higher Dose Oral Fluconazole for the Treatment of AIDS-related Cryptococcal Meningitis (HIFLAC)—report of A5225, a multicentre, phase I/II, two-stage, dose-finding, safety, tolerability and efficacy randomised, amphotericin B-controlled trial of the AIDS Clinical Trials Group. PLoS ONE, 17(2), 1–21. https://doi.org/10.1371/journal.pone.0281580

Chicago

Lalloo, Umesh G., Lauren Komarow, Judith A. Aberg, David B. Clifford, Evelyn Hogg, Ashley McKhann, Aggrey Bukuru, et al. 2023. “Higher Dose Oral Fluconazole for the Treatment of AIDS-Related Cryptococcal Meningitis (HIFLAC)—report of A5225, a Multicentre, Phase I/II, Two-Stage, Dose-Finding, Safety, Tolerability and Efficacy Randomised, Amphotericin B-Controlled Trial of the AIDS Clinical Trials Group.” PLoS ONE 17 (2): 1–21. doi:10.1371/journal.pone.0281580.